Sorrento Therapeutics Inc. (SRNE) News
Filter SRNE News Items
SRNE News Results
|Loading, please wait...|
SRNE News Highlights
- SRNE's 30 day story count now stands at 21.
- Over the past 28 days, the trend for SRNE's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
- MSC, DAR and AMG are the most mentioned tickers in articles about SRNE.
Latest SRNE News From Around the Web
Below are the latest news stories about Sorrento Therapeutics Inc that investors may wish to consider to help them evaluate SRNE as an investment opportunity.
SORRENTO INVESTIGATION INITIATED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sorrento Therapeutics, Inc. - SRNE
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Sorrento Therapeutics, Inc. (NasdaqGS: SRNE).
Sorrento Therapeutics (SRNE) has filed to sell ~851K shares from selling shareholder Icahn School of Medicine at Mount Sinai.The proposed aggregate maximum offering price is ~$6.47M.Last month, Mount Sinai licensed to Sorrento antibodies that could be used as SARS-CoV-2 treatment.Sorrento shares are down 0.1% to $7.50 in after-market trading....
Which stock has more potential for growth over the next year? Let's look to the stars for an answer.
Sorrento (SRNE) is not a company to rest on its laurels, particularly on the acquisition front. There have been several additions to the biotech’s ever-expanding pipeline over the past few months, and April is proving no different. Earlier this week, Sorrento announced it is acquiring late-stage oncology company ACEA Therapeutics, in an all-stock deal worth $38 million. ACEA equity holders could also be eligible for milestone payments up to $450 million and 5-10% royalties from annual net sales. The merger is anticipated to close sometime in the second quarter.
Shares of Sorrento Therapeutics increased 3.3% to close at $8.27 on April 5 after the clinical-stage antibody-centric biopharmaceutical company agreed to snap up late-stage oncology company ACEA Therapeutics. Along with ACEA’s late clinical-stage drug Abivertinib, clinical-stage candidate AC0058, pre-clinical-stage candidate AC0939, and extensive proprietary library of small molecules, Sorrento (SRNE) will also acquire ACEA’s China-based state of the art cGMP facility on 23 acres of land with five buildings. The acquisition, which awaits regulatory approvals, is likely to close in the second quarter of 2021. Previously in Oct. 2020, a letter of intent was signed, including the terms and conditions of the deal.
Sorrento Therapeutics Inc (NASDAQ: SRNE) has agreed to acquire ACEA Therapeutics Inc in an all-stock deal of $38 million in shares of Sorrento common stock. Sorrento will also pay the ACEA up to $450 million in additional milestone payments and 5-10% royalty of the annual net sales. The acquisition will include late clinical-stage drug Abivertinib, AC0058, AC0939, and ACEA's extensive proprietary library of small molecules (over 1,000,000 compounds). Lead candidate abivertinib is a small molecule tyrosine kinase inhibitor that selectively targets both a mutant form of the epidermal growth factor receptor and Bruton's tyrosine kinase. It is currently being studied as a Phase 2 treatment for COVID-19-induced respiratory compromise in the U.S. and Brazil. AC0058 a BTK inhibitor, is current...
ACEA’s major assets include: Abivertinib (in oral capsule form), a next generation, dual EGFR mutant and BTK inhibitor (BTKi) with a completed NSCLC registrational/Phase 3 trial, Phase 1 B-cell lymphoma study, and ongoing Phase 2 trials in COVID-19 patients with ARDS, and Phase 2 studies for prostate cancer, systemic lupus erythematosus and the ultra-orphan indication of hairy cell leukemia.AC0058, a brain-penetrating, next generation BTK inhibitor in a Phase 1b Lupus trial and IND-enabling studies for multiple sclerosis.AC0939, a next generation FLT-3 inhibitor, is near completion of IND-enabling studies for potential CNS indications.A 1,000,000+ compound library of small molecules and proprietary discovery platform for screening and optimizing potent drug candidates for potential indi...
Once a specialist in oncology drugs and pain management, last year, Sorrento Therapeutics (SRNE) refocused its business on addressing the threat from COVID-19. One year later, the company is viewed primarily as a COVID play. On Thursday, Sorrento reported that in a single arm, non-randomized Phase 1b study of its human allogeneic adipose-derived mesenchymal stem cells (those are the "MSC" in the name "COVI-MSC"), "all nine patients responded rapidly with markedly reduced need for high inspired oxygen concentration and were able to be transferred out of the ICU and discharged from the hospital within several days of their 3rd COVI-MSC infusion.
Controversial billionaire scientist Dr. Patrick Soon-Shiong discusses COVID-19 vaccine efforts.
Sorrento Therapeutics (SRNE) posts updated positive results from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) for patients suffering from COVID-19-induced acute respiratory distress ((ARD)) or acute respiratory distress syndrome ((ARDS)).The study is a single arm, non-randomized early-stage study of the safety and preliminary efficacy of COVI-MSCs administered every other day for three infusions for a total of 1 x 106 cells/kg, with the main...